- Home
- FLYW vs NVAX Comparison
FLYW vs NVAX Comparison
Compare FLYW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYW
- NVAX
- Stock Information
- Founded
- FLYW 2009
- NVAX 1987
- Country
- FLYW United States
- NVAX United States
- Employees
- FLYW N/A
- NVAX N/A
- Industry
- FLYW Computer Software: Prepackaged Software
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLYW Technology
- NVAX Health Care
- Exchange
- FLYW Nasdaq
- NVAX Nasdaq
- Market Cap
- FLYW 2.2B
- NVAX 2.0B
- IPO Year
- FLYW 2021
- NVAX 1995
- Fundamental
- Price
- FLYW $20.13
- NVAX $8.70
- Analyst Decision
- FLYW Strong Buy
- NVAX Buy
- Analyst Count
- FLYW 13
- NVAX 6
- Target Price
- FLYW $25.31
- NVAX $17.83
- AVG Volume (30 Days)
- FLYW 1.4M
- NVAX 3.8M
- Earning Date
- FLYW 11-07-2024
- NVAX 11-12-2024
- Dividend Yield
- FLYW N/A
- NVAX N/A
- EPS Growth
- FLYW N/A
- NVAX N/A
- EPS
- FLYW 0.16
- NVAX N/A
- Revenue
- FLYW $475,139,000.00
- NVAX $885,193,000.00
- Revenue This Year
- FLYW $23.63
- NVAX N/A
- Revenue Next Year
- FLYW $24.41
- NVAX N/A
- P/E Ratio
- FLYW $123.88
- NVAX N/A
- Revenue Growth
- FLYW 26.50
- NVAX N/A
- 52 Week Low
- FLYW $15.19
- NVAX $3.53
- 52 Week High
- FLYW $31.54
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- FLYW 43.66
- NVAX 46.62
- Support Level
- FLYW $19.83
- NVAX $8.50
- Resistance Level
- FLYW $21.75
- NVAX $9.75
- Average True Range (ATR)
- FLYW 0.76
- NVAX 0.50
- MACD
- FLYW -0.26
- NVAX 0.06
- Stochastic Oscillator
- FLYW 8.82
- NVAX 35.19
About FLYW Flywire Corporation Voting
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary global payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.